Sleiman J, Charabaty A, Rahman A ur. Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?. Gijournal [Internet]. 2021Aug.31 [cited 2026Sep.11];1(1). Available from: https://gijournal.org/index.php/gijournal/article/view/23